The monkeypox (MPX) is an unusual viral disease which, until recently, has rarely been detected outside of Africa. A total of 71,237 confirmed cases of MPX, as of October 6th, 2022, had been discovered in 109 countries in the matter of months. The risk factors of MPX are men who have sex with the same gender (prevalence 90.0%, 95% CI, 89.5 to 90.4), sexual exposure to sex partners with MPX (prevalence 87.3%, 95% CI 6.7 to 87.8), human immunodeficiency virus-positive individuals (prevalence 49.1%, 95% CI, 48.4 to 49.8), people who have travel history to Africa (prevalence 16.9%, 95% CI, 16.2 to 17.7), hospitalization (prevalence 7.3%, 95% CI 7.0 to 7.6), health workers (prevalence 3.2%, 95% CI 2.9 to 3.5), admission to intensive care unit (prevalence 0.18%, 95% CI 0.11 to 0.28), and death (prevalence 0.03%, 95% CI 0.02 to 0.06). According to an international cohort of 60,510 individuals, the MPX can result in rash (all types; 83.6%, n=21,472), fever (57.8%, n=14,842), rash on the whole body (49.6%, n=12,730), genital rash (45.5%, n=11,696), headache (29.4%, n=7,556), fatigue (29.3%, n=7,523), lymphadenopathy(all types) (29.0%, n=7,453), muscle ache (26.9%, n=6,919), general lymphadenopathy (24.3%, n=6,235), local lymphadenopathy (18.6%, n=4,779), rash of unknown location (12.7%, n=3,271), sore throat, oral rash, chills, cough, vomiting, and other signs and/or symptoms in the order of frequency, with a subtle difference between men and women. The median delay between the date of onset and reporting was 6 days (interquartile range, 3 to 9). Results that an African endemic virus has been identified more in worldwide populations than in Africa has shocked scientists which led to the question of why an African disease is becoming a global illness and why the world is currently encountering this problem.